Vaccitech, which developed the technology underlying Oxford’s covid vaccine, has priced its shares and will raise more than $110m in its IPO.

Vaccitech, a UK-based vaccine developer spun out of University of Oxford, priced its shares at $17 yesterday and will raise more than $110m when it begins trading on the Nasdaq Global Market today.
The spinout will issue 6.5 million American Depositary Shares (ADSs), representing the same number of ordinary shares. It will trade using the ticker symbol VACC.
Founded in 2016, Vaccitech initially aimed to develop a universal flu vaccine but the technology’s arguably most fundamental impact…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in